Layoffs
Ultragenyx lays off 20% of workforce and axes drug programs to halve R&D spend
Key Facts
Signal Type
Layoffs
Industry
Biotech
Companies
Ultragenyx
Date
Ultragenyx announced a 20% workforce reduction (approximately 370 employees) after market close on Tuesday, aiming to cut its annual R&D budget in half by 2027. The biopharma is winding down all studies of GTX-102 (Angelman syndrome) following a failed Phase 3 trial and ending development of UX701 (Wilson disease) due to lackluster data. CEO Emil Kakkis stated the company will shift resources from early-stage R&D to growing sales of its six commercial products, with most of the proposed $350 million 2027 R&D budget earmarked for commercial programs, monitoring, and regulatory filings.
The layoffs primarily impact R&D staff, as Ultragenyx reduces its workforce from 1,371 to approximately 1,000 employees. The company is also shrinking its real estate footprint as part of cost-containment. The two discontinued programs—GTX-102 and UX701—will see all ongoing studies wound down, affecting patients and partners involved in those trials. Remaining pipeline programs include DTX301 (Phase 3 for OTC deficiency) and setrusumab (antibody for osteogenesis imperfecta), though the latter faces regulatory hurdles after two Phase 3 failures.
Monitor Ultragenyx’s progress toward profitability in 2027, including any new licensing deals or partnerships that align with its “small, smart deals” strategy. The fate of setrusumab and DTX301 will be key pipeline milestones. Additionally, watch for further real estate dispositions and any follow-on layoffs as the company completes the restructuring this year.
Source:
Fierce BiotechGet biotech signals in your CRM
FDA approvals and rejections, clinical trial results, pharma M&A, drug recalls, and funding rounds.
